Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (65)

Latest Posts

About This Stock More About This Stock
IBB – Challenging 2016, Recovering 2017 And Resurgence In 2018
Article By: Noah Kiedrowski
Tuesday, February 6, 2018 3:12 PM EST
The Biotechnology cohort has finally notched a 52-week high and has made up much of the lost ground during the pummeling from both sides of the political isle during the 2016 presidential race.
In this article: AGN, JNJ, NVO, IBB, REGN, GILD, JUNO, ABBV, KITE
Read
Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
Article By: Insider Monkey
Tuesday, January 30, 2018 8:03 PM EST
Investment manager Polen Capital is bullish on Regeneron Pharmaceuticals (REGN), which has six FDA-approved medicines and numerous product candidates in a range of diseases.
In this article: REGN
Read
Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant
Article By: Rod Raynovich
Friday, January 26, 2018 6:44 PM EST
Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.
In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA
Read
Family-Owned Firms: Trading At A Discount
Article By: ValueWalk
Saturday, October 7, 2017 9:39 PM EST
Ffor each of the past ten years, family-owned companies have shown stronger revenue growth than their non-family-owned peers. Also, R&D spending has been higher, balance sheets strong and margins wider.
In this article: CCW, LVMHF, REGN, CMCSA, ORCL, FB, FOX
Read
Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
Article By: Zacks Investment Research
Monday, September 11, 2017 4:50 PM EST
Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.
In this article: SNY, REGN Also: ALXN, ADRO
Read

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!

$REGN

Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments